Phathom Pharmaceuticals Appoints Frank Karbe to its Board of Directors
FLORHAM PARK, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Frank Karbe to its Board of Directors. Mr. Karbe, who most recently served as President and Chief Financial Officer of Myovant Sciences, Inc. (NYSE:MYOV), brings over twenty-five years of financial and life-sciences expertise to Phathom.
“We are thrilled to welcome Frank to our Board as we approach a critical inflection point for Phathom,” said Terrie Curran, President and Chief Executive Officer of Phathom. “Frank’s financial, business development, and corporate strategy expertise and strong record of readying organizations for commercialization will help guide the execution of our strategic vision.”
As President and Chief Financial Officer of Myovant, Mr. Karbe led the company’s efforts to raise approximately $2 billion in capital and its evolution from a private start-up organization to a publicly listed commercial-stage company with two approved and marketed products. Prior to Myovant, Mr. Karbe served as Executive Vice President and Chief Financial Officer at Exelixis, Inc. (Nasdaq: EXEL), where he drove the biopharma company’s transformation from discovery to commercialization. Earlier in his career, he worked as an investment banker for Goldman Sachs & Co. focusing on corporate finance and mergers and acquisitions in the life sciences industry. Mr. Karbe has previously served on the Board of Directors of Aduro Biotech, Arbutus Biopharma Corporation, and Kolltan Pharmaceuticals, Inc. Mr. Karbe holds a Diplom-Kaufmann (MBA) from the WHU Otto Beisheim School of Management in Koblenz, Germany.
About Phathom
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders. For more information about Phathom, visit the Company’s website at www.phathompharma.com and follow the Company on LinkedIn and Twitter.
CONTACTS
Media and Investor Contact:
Nick Benedetto
1-877-742-8466
media@phathompharma.com
ir@phathompharma.com
